BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
BridgeBio Pharma's enterprise value was $14.82B on Nov 11, 2026, against $13.24B a year earlier. Over the last 5 years it ranged from $590.29M to $14.82B, with a median of $5.30B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $14.82B | +5.1% |
| 2025 | Dec 31, 2025 | $14.10B | +162.7% |
| 2024 | Dec 31, 2024 | $5.37B | -23.1% |
| 2023 | Dec 29, 2023 | $6.98B | +1082.2% |
| 2022 | Dec 30, 2022 | $590.29M | -69.9% |
| 2021 | Dec 31, 2021 | $1.96B | -75.9% |
| 2020 | Dec 31, 2020 | $8.15B | +119.4% |
| 2019 | Dec 31, 2019 | $3.71B | – |
See a number that looks wrong?